-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chondrosarcoma (CS) is a heterogeneous mesenchymal tumor and the second most common primary bone tumor in adults, accounting for about 20% of primary bone tumors.
In the past 30 years, the survival rate of patients with metastatic chondrosarcoma has hardly improved
A multi-cohort clinical trial explored the efficacy and safety of multi-target tyrosine kinase inhibitor regorafenib for advanced sarcoma of bone origin; this article details the use of regorafenib after previous chemotherapy Efficacy and safety analysis results in a cohort of patients with advanced locally advanced or metastatic chondrosarcoma.
CS patients were randomly assigned (2:1) to regorafenib group or placebo group.
Progression-free survival
Progression-free survivalFrom September 2014 to February 2019, a total of 46 patients were enrolled in the CS cohort, of which 40 were available for efficacy analysis: 24 in the regorafenib group and 16 in the placebo group.
At 12 weeks, 13 patients (54.
Adverse events
Adverse eventsThe most common treatment-related adverse events of grade 3 and above in the regorafenib group were hypertension (12%), weakness (8%), thrombocytopenia (8%) and diarrhea (8%).
In conclusion, although the primary endpoint did not reach statistical significance in this small randomized cohort trial, there is sufficient evidence that regorafenib may slow the progression of the disease course in patients with metastatic CS who have failed previous chemotherapy .
Although in this small randomized cohort trial, the primary endpoint did not reach statistical significance, there is sufficient evidence that regorafenib may slow the progression of the disease course in patients with metastatic CS who have failed previous chemotherapy
Original source:
Original source:Duffaud Florence,Italiano Antoine,Bompas Emannuelle et al.
org/10.
1016/j.
ejca.
2021.
03.
039" target="_blank" rel="noopener">Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study in this message
